Cyclin Time Critical in Assessing Patients with COVID-19 and Leukemia
Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on how health care providers can effectively care for patients with COVID-19 and hematologic malignancies.
Health care providers can effectively care for patients with COVID-19 and hematologic malignancies, said Stephanie Jackson DNP, MSN, RN, AOCNS, BMTCN.
Jackson, unit director, hematology/stem cell transplantation, UCLA, recently presented on leukemia essentials for the oncology nurse at the 5th Annual School of Nursing Oncology. In an interview, Jackson, who is also co-editor in chief of Oncology Nursing News, discussed the increased risk for COVID-19 that individuals with leukemia face, and how providers have adjusted their care strategies in response to the virus.
“What we do whenever we have a patient that has had COVID, we look at their cyclin time, because it may not manifest on the COVID-19 test,” said Jackson, “but we look at the cyclin time of that virus, to see how quickly it’s replicating, and to see how many antibodies they have to make sure that we’re watching that over a scheduled amount of time.”
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.
